Welcome to our dedicated page for Regulus Therapeu news (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeu stock.
Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical innovator focused on developing microRNA-targeted therapies through advanced oligonucleotide technology. This page serves as the definitive source for official company announcements, research milestones, and regulatory developments.
Investors and researchers will find timely updates on clinical trial progress, including the Phase 1b study of RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD). Our curated news collection provides essential insights into therapeutic advancements, partnership agreements, and strategic initiatives shaping the company's trajectory.
The repository features rigorously verified information across key categories: clinical program updates, financial disclosures, intellectual property developments, and scientific publications. Each entry maintains factual accuracy while highlighting implications for Regulus' position in the precision medicine landscape.
Bookmark this page for direct access to primary source materials from Regulus Therapeutics. Regularly updated content ensures stakeholders maintain current understanding of the company's progress in addressing complex diseases through RNA-targeted therapeutics.
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeted medicines, announced that its CEO, Jay Hagan, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A replay of the on-demand presentation will be accessible from March 9, 2021, on their website for 30 days. Regulus focuses on innovative drug discovery, maintaining a robust pipeline and intellectual property in the microRNA sector, headquartered in La Jolla, CA.
Regulus Therapeutics (Nasdaq: RGLS) has completed the enrollment of the first cohort in its Phase 1b clinical trial of RGLS4326 for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). This open-label study evaluates safety and pharmacokinetics, with the first cohort receiving 1mg/kg of RGLS4326. Interim safety data has led to the first patient in the second cohort receiving their dose. No serious adverse events have been reported, and results from the first cohort are anticipated in early Q2 2021.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the appointment of Alice S. Huang, Ph.D., to its board of directors, effective January 27, 2021. In addition to her board role, she will serve on the Compensation Committee. Dr. Huang is a Senior Faculty Associate at the California Institute of Technology and has an extensive background in biology and biomedical research, having held significant positions at prestigious institutions. The company believes her expertise will enhance its drug discovery and development efforts.
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on microRNA-targeted medicines, will be presenting at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. Jay Hagan, President and CEO, will lead the presentation. An on-demand webcast will be accessible starting January 11, 2021, via the investor relations section of Regulus' website. The company, headquartered in La Jolla, CA, emphasizes its expertise in oligonucleotide drug discovery and holds a strong intellectual property portfolio.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the closing of a private placement, raising approximately $19.4 million by selling 24,341,607 shares of common stock at $0.622 each. Additionally, 272,970 shares of non-voting Class A-3 convertible preferred stock were sold at $6.22 per share. The proceeds will primarily support the advancement of RGLS4326 for treating Autosomal Dominant Polycystic Kidney Disease and for general corporate purposes. H.C. Wainwright and Co. acted as the exclusive placement agent for this financing.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced a definitive securities purchase agreement for a private placement expected to raise approximately $19.4 million from existing and new institutional investors. The financing includes the sale of about 24.3 million shares of Common Stock priced at $0.7158 per share, along with accompanying warrants. Additionally, 272,970 shares of non-voting Class A-3 convertible preferred stock will be sold at $6.22 per share. The closing is anticipated on December 3, 2020, pending customary conditions.
Regulus Therapeutics Inc. (Nasdaq: RGLS) reported Q3 2020 financial results, highlighting a revenue increase to $5 million, up from less than $0.1 million in Q3 2019. The company announced the dosing of the first patient in its Phase 1b clinical trial for RGLS4326 targeting ADPKD. Milestones from collaboration with Sanofi, totaling $10 million, allowed a reduction of debt to $4.7 million. R&D expenses rose to $4 million, reflecting ongoing study activities. Net loss narrowed to $1.5 million, or $0.04 per share, compared to a $5.4 million loss in Q3 2019.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the achievement of a $5 million milestone from its collaboration with Sanofi for the miR-21 programs, triggered by patient enrollment in the Phase 2 clinical study of RG-012 for Alport Syndrome. This funding will reduce the term loan with Oxford LLC to approximately $4.7 million and extend interest-only payments through 2021. The company previously reported positive trends in kidney disease markers from a Phase 1b study of RG-012, which has orphan designation in both the U.S. and Europe. Additionally, Regulus is eligible for another $25 million in 2023 upon reaching a development milestone.
Regulus Therapeutics (Nasdaq: RGLS) has initiated dosing in a Phase 1b clinical study of RGLS4326 for patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). This study aims to assess safety, pharmacokinetics, and biomarker changes in up to three cohorts. The first cohort will consist of nine patients receiving RGLS4326 biweekly for six weeks, with results expected by the end of Q1 2021. Regulus aims to use these results to address FDA requirements for extended-duration studies. RGLS4326 targets microRNAs to elevate polycystin levels linked to ADPKD.
Regulus Therapeutics (Nasdaq: RGLS) announced the receipt of $5 million from Sanofi as part of milestone and material payments related to its miR-21 programs. The company utilized these funds to pay down its term loan to approximately $9.6 million. Regulus is eligible for additional payments, including $5 million upon achieving an interim milestone and $25 million for a development milestone. The loan agreement with Oxford includes provisions for an additional interest-only period if the company pays down another $5 million by April 30, 2021.
